Seroatlas · Human Serome Atlas

NEK9

Serine/threonine-protein kinase Nek9

Also known as: DKFZp434D0935, MGC16714, Nek8, NEK9_HUMAN, NERCC, NERCC1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8TD19
Gene: NEK9
Ensembl: ENSG00000119638
Chromosome: 14
Canonical length: 979 aa
Protein class: Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters
Quaternary structure: Homodimer

OverviewNCBI Gene

This gene encodes a member of the NimA (never in mitosis A) family of serine/threonine protein kinases. The encoded protein is activated in mitosis and, in turn, activates other family members during mitosis. This protein also mediates cellular processes that are essential for interphase progression. [provided by RefSeq, Jul 2016]

Canonical amino-acid sequenceUniProt

979 residues, UniProt reviewed canonical sequence.

>Q8TD19|NEK9
     1  MSVLGEYERH CDSINSDFGS ESGGCGDSSP GPSASQGPRA GGGAAEQEEL HYIPIRVLGR
    61  GAFGEATLYR RTEDDSLVVW KEVDLTRLSE KERRDALNEI VILALLQHDN IIAYYNHFMD
   121  NTTLLIELEY CNGGNLYDKI LRQKDKLFEE EMVVWYLFQI VSAVSCIHKA GILHRDIKTL
   181  NIFLTKANLI KLGDYGLAKK LNSEYSMAET LVGTPYYMSP ELCQGVKYNF KSDIWAVGCV
   241  IFELLTLKRT FDATNPLNLC VKIVQGIRAM EVDSSQYSLE LIQMVHSCLD QDPEQRPTAD
   301  ELLDRPLLRK RRREMEEKVT LLNAPTKRPR SSTVTEAPIA VVTSRTSEVY VWGGGKSTPQ
   361  KLDVIKSGCS ARQVCAGNTH FAVVTVEKEL YTWVNMQGGT KLHGQLGHGD KASYRQPKHV
   421  EKLQGKAIRQ VSCGDDFTVC VTDEGQLYAF GSDYYGCMGV DKVAGPEVLE PMQLNFFLSN
   481  PVEQVSCGDN HVVVLTRNKE VYSWGCGEYG RLGLDSEEDY YTPQKVDVPK ALIIVAVQCG
   541  CDGTFLLTQS GKVLACGLNE FNKLGLNQCM SGIINHEAYH EVPYTTSFTL AKQLSFYKIR
   601  TIAPGKTHTA AIDERGRLLT FGCNKCGQLG VGNYKKRLGI NLLGGPLGGK QVIRVSCGDE
   661  FTIAATDDNH IFAWGNGGNG RLAMTPTERP HGSDICTSWP RPIFGSLHHV PDLSCRGWHT
   721  ILIVEKVLNS KTIRSNSSGL SIGTVFQSSS PGGGGGGGGG EEEDSQQESE TPDPSGGFRG
   781  TMEADRGMEG LISPTEAMGN SNGASSSCPG WLRKELENAE FIPMPDSPSP LSAAFSESEK
   841  DTLPYEELQG LKVASEAPLE HKPQVEASSP RLNPAVTCAG KGTPLTPPAC ACSSLQVEVE
   901  RLQGLVLKCL AEQQKLQQEN LQIFTQLQKL NKKLEGGQQV GMHSKGTQTA KEEMEMDPKP
   961  DLDSDSWCLL GTDSCRPSL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NEK9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.37
Highest tissue expression: 41 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 41 nTPM
heart muscle: 35 nTPM
tongue: 35 nTPM
parathyroid gland: 32 nTPM
smooth muscle: 30 nTPM
ovary: 29 nTPM

Single-cell type

cardiomyocytes: 184 nCPM
myonuclei: 124 nCPM
pancreatic islet cells: 121 nCPM
adrenal cortex cells: 93 nCPM
adipocytes: 87 nCPM
sertoli cells: 87 nCPM

Immune cell

myeloid DC: 5.1 nTPM
MAIT T-cell: 4 nTPM
classical monocyte: 3.5 nTPM
intermediate monocyte: 3.4 nTPM
basophil: 3.3 nTPM
NK-cell: 3.3 nTPM

Brain region

choroid plexus: 16 nTPM
white matter: 15 nTPM
basal ganglia: 14 nTPM
medulla oblongata: 14 nTPM
hypothalamus: 13 nTPM
midbrain: 13 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about NEK9.

Disease | AllUniProt

Conditions NEK9 is implicated in, by any mechanism.

Lethal congenital contracture syndrome 10 (LCCS10) MIM:617022
Nevus comedonicus (NC) MIM:617025
Arthrogryposis, Perthes disease, and upward gaze palsy (APUG) MIM:614262

Disease | GeneticClinVar

22 pathogenic / likely-pathogenic of 235 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

NEK9-related lethal skeletal dysplasia
Arthrogryposis, Perthes disease, and upward gaze palsy
Nevus comedonicus syndrome
Goldberg-Shprintzen syndrome
Inborn genetic diseases

Disease | ImmuneIEDB

Conditions an epitope on NEK9 was assayed in.

narcolepsy B cell
multiple sclerosis B cell
peripheral nervous system disease B cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.86
gnomAD pLI: 0
gnomAD missense Z: 2.5
DepMap mean gene effect: -0.07
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

Regulator of chromosome condensation, RCC1
Protein kinase domain
Serine/threonine-protein kinase, active site
Regulator of chromosome condensation 1/beta-lactamase-inhibitor protein II
Protein kinase-like domain superfamily
Serine/threonine-protein kinase NEK
RCC1-like domain
Protein kinase domain
RCC1-like domain
Serine/threonine-protein kinase Nek9, catalytic domain

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of NEK9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NEK9 as an antibody target. Whether an autoantibody or antibody against NEK9 could matter depends on whether native NEK9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NEK9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label NEK9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...